Using yeast to model calcium-related diseases: Example of the Hailey-Hailey disease

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1843, Issue 10, 2014, Pages 2315-2321

  Voisset, Cécile ^a   García Rodríguez, Néstor ^b   Birkmire, April ^b   Blondel, Marc ^a   Wellinger, Ralf Erik ^a,b  

^a UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^b UNIVERSITY OF SEVILLE   (Spain)

Author keywords

ATP2C1 PMR1; Budding yeast Saccharomyces cerevisiae; Calcium; Hailey Hailey disease; Yeast models for human diseases; Yeast based drug screening assay

Indexed keywords

CALCIUM;

CHEMICAL MODIFICATION; DISEASE MODEL; DRUG SCREENING; HAILEY HAILEY DISEASE; HUMAN; MOLECULE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SACCHAROMYCES CEREVISIAE; YEAST;

ATP2C1/PMR1; BUDDING YEAST SACCHAROMYCES CEREVISIAE; CALCIUM; HAILEY-HAILEY DISEASE; YEAST MODELS FOR HUMAN DISEASES; YEAST-BASED DRUG SCREENING ASSAY;

ADMINISTRATION, CUTANEOUS; CALCIUM; CALCIUM SIGNALING; CALCIUM-TRANSPORTING ATPASES; DERMATOLOGIC AGENTS; DIHYDROXYCHOLECALCIFEROLS; GENE EXPRESSION; HUMANS; KERATINOCYTES; MODELS, BIOLOGICAL; MOLECULAR CHAPERONES; MUTATION; PEMPHIGUS, BENIGN FAMILIAL; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS; SKIN;

EID: 84904910805     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2014.02.011     Document Type: Review

References (121)

1. Goffeau A., Barrell B.G., Bussey H., Davis R.W., Dujon B., Feldmann H., Galibert F., Hoheisel J.D., Jacq C., Johnston M., Louis E.J., Mewes H.W., Murakami Y., Philippsen P., Tettelin H., Oliver S.G. Life with 6000 genes. Science 1996, 274:546, 563-546, 567.
2. St Onge R., Schlecht U., Scharfe C., Evangelista M. Forward chemical genetics in yeast for discovery of chemical probes targeting metabolism. Molecules 2012, 17:13098-13115.
3. Schatz G., Haslbrunner E., Tuppy H. Deoxyribonucleic acid associated with yeast mitochondria. Biochem. Biophys. Res. Commun. 1964, 15:127-132.
4. Hartwell L.H. Nobel lecture. Yeast and cancer. Biosci. Rep. 2002, 22:373-394.
5. Nurse P.M. Nobel lecture. Cyclin dependent kinases and cell cycle control. Biosci. Rep. 2002, 22:487-499.
6. Galons H., Oumata N., Meijer L. Cyclin-dependent kinase inhibitors: a survey of recent patent literature. Expert Opin. Ther. Pat. 2010, 20:377-404.
7. Galons H., Oumata N., Gloulou O., Meijer L. Cyclin-dependent kinase inhibitors closer to market launch?. Expert Opin. Ther. Pat. 2013, 23:945-963.
8. Bassett D.E., Boguski M.S., Hieter P. Yeast genes and human disease. Nature 1996, 379:589-590.
9. Mager W.H., Winderickx J. Yeast as a model for medical and medicinal research. Trends Pharmacol. Sci. 2005, 26:265-273.
10. Perocchi F., Mancera E., Steinmetz L.M. Systematic screens for human disease genes, from yeast to human and back. Mol. Biosyst. 2008, 4:18-29.
11. Ishioka C., Frebourg T., Yan Y.X., Vidal M., Friend S.H., Schmidt S., Iggo R. Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nat. Genet. 1993, 5:124-129.
12. Schärer E., Iggo R. Mammalian p53 can function as a transcription factor in yeast. Nucleic Acids Res. 1992, 20:1539-1545.
13. Szczebara F.M., Chandelier C., Villeret C., Masurel A., Bourot S., Duport C., Blanchard S., Groisillier A., Testet E., Costaglioli P., Cauet G., Degryse E., Balbuena D., Winter J., Achstetter T., Spagnoli R., Pompon D., Dumas B. Total biosynthesis of hydrocortisone from a simple carbon source in yeast. Nat. Biotechnol. 2003, 21:143-149.
14. Westfall P.J., Pitera D.J., Lenihan J.R., Eng D., Woolard F.X., Regentin R., Horning T., Tsuruta H., Melis D.J., Owens A., Fickes S., Diola D., Benjamin K.R., Keasling J.D., Leavell M.D., McPhee D.J., Renninger N.S., Newman J.D., Paddon C.J. Production of amorphadiene in yeast, and its conversion to dihydroartemisinic acid, precursor to the antimalarial agent artemisinin. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E111-E118.
15. Baile M.G., Claypool S.M. The power of yeast to model diseases of the powerhouse of the cell. Front. Biosci. (Landmark Ed.) 2013, 18:241-278.
16. Couplan E., Aiyar R.S., Kucharczyk R., Kabala A., Ezkurdia N., Gagneur J., Onge R.P.S., Salin B., Soubigou F., Cann M.L., Steinmetz L.M., Rago J.-P.D., Blondel M. A yeast-based assay identifies drugs active against human mitochondrial disorders. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:11989-11994.
17. Schwimmer C., Lefebvre-Legendre L., Rak M., Devin A., Slonimski P.P., di Rago J.P., Rigoulet M. Increasing mitochondrial substrate-level phosphorylation can rescue respiratory growth of an ATP synthase-deficient yeast. J. Biol. Chem. 2005, 280:30751-30759.
18. Remacle C., Cardol P., Coosemans N., Gaisne M., Bonnefoy N. High-efficiency biolistic transformation of Chlamydomonas mitochondria can be used to insert mutations in complex I genes. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:4771-4776.
19. Bonnefoy N., Fox T.D. Genetic transformation of Saccharomyces cerevisiae mitochondria. Methods Cell Biol. 2001, 65:381-396.
20. Blondel M. Flirting with CFTR modifier genes at happy hour. Genome Med. 2012, 4:98.
21. Louie R.J., Guo J., Rodgers J.W., White R., Shah N.A., Pagant S., Kim P., Livstone M., Dolinski K., McKinney B.A., Hong J., Sorscher E.J., Bryan J., Miller E.A., Hartman Iv J.L. A yeast phenomic model for the gene interaction network modulating CFTR-δF508 protein biogenesis. Genome Med. 2012, 4:103.
22. Bach S., Talarek N., Andrieu T., Vierfond J.M., Mettey Y., Galons H., Dormont D., Meijer L., Cullin C., Blondel M. Isolation of drugs active against mammalian prions using a yeast-based screening assay. Nat. Biotechnol. 2003, 21:1075-1081.
23. Bach S., Tribouillard D., Talarek N., Desban N., Gug F., Galons H., Blondel M. A yeast-based assay to isolate drugs active against mammalian prions. Methods 2006, 39:72-77.
24. Tribouillard D., Bach S., Gug F., Desban N., Beringue V., Andrieu T., Dormont D., Galons H., Laude H., Vilette D., Blondel M. Using budding yeast to screen for anti-prion drugs. Biotechnol. J. 2006, 1:58-67.
25. Oumata N., Nguyen P.H., Beringue V., Soubigou F., Pang Y., Desban N., Massacrier C., Morel Y., Paturel C., Contesse M.A., Bouaziz S., Sanyal S., Galons H., Blondel M., Voisset C. The toll-like receptor agonist imiquimod is active against prions. PLoS One 2013, 8:e72112.
26. Tribouillard-Tanvier D., Béringue V., Desban N., Gug F., Bach S., Voisset C., Galons H., Laude H., Vilette D., Blondel M. Antihypertensive drug guanabenz is active in vivo against both yeast and mammalian prions. PLoS One 2008, 3:e1981.
27. Tribouillard-Tanvier D., Dos Reis S., Gug F., Voisset C., Béringue V., Sabate R., Kikovska E., Talarek N., Bach S., Huang C., Desban N., Saupe S.J., Supattapone S., Thuret J.Y., Chédin S., Vilette D., Galons H., Sanyal S., Blondel M. Protein folding activity of ribosomal RNA is a selective target of two unrelated antiprion drugs. PLoS One 2008, 3:e2174.
28. Pang Y., Kurella S., Voisset C., Samanta D., Banerjee D., Schabe A., Das Gupta C., Galons H., Blondel M., Sanyal S. The antiprion compound 6-aminophenanthridine inhibits the protein folding activity of the ribosome by direct competition. J. Biol. Chem. 2013, 288:19081-19089.
29. Reis S.D., Pang Y., Vishnu N., Voisset C., Galons H., Blondel M., Sanyal S. Mode of action of the antiprion drugs 6AP and GA on ribosome assisted protein folding. Biochimie 2011, 93:1047-1054.
30. Giorgini F., Guidetti P., Nguyen Q., Bennett S.C., Muchowski P.J. A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat. Genet. 2005, 37:526-531.
31. Zhang X., Smith D.L., Meriin A.B., Engemann S., Russel D.E., Roark M., Washington S.L., Maxwell M.M., Marsh J.L., Thompson L.M., Wanker E.E., Young A.B., Housman D.E., Bates G.P., Sherman M.Y., Kazantsev A.G. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:892-897.
32. Outeiro T.F., Lindquist S. Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 2003, 302:1772-1775.
33. Zwilling D., Huang S.Y., Sathyasaikumar K.V., Notarangelo F.M., Guidetti P., Wu H.Q., Lee J., Truong J., Andrews-Zwilling Y., Hsieh E.W., Louie J.Y., Wu T., Scearce-Levie K., Patrick C., Adame A., Giorgini F., Moussaoui S., Laue G., Rassoulpour A., Flik G., Huang Y., Muchowski J.M., Masliah E., Schwarcz R., Muchowski P.J. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 2011, 145:863-874.
34. Orrenius S., Zhivotovsky B., Nicotera P. Regulation of cell death: the calcium-apoptosis link. Nat. Rev. Mol. Cell Biol. 2003, 4:552-565.
35. 2+-transporting ATPases. Am. J. Physiol. Cell Physiol. 2004, 287:C580-C589.
36. Clapham D.E. Calcium signaling. Cell 2007, 131:1047-1058.
37. Jaiswal J.K. Calcium - how and why?. J. Biosci. 2001, 26:357-363.
38. Koch G.L. The endoplasmic reticulum and calcium storage. Bioessays 1990, 12:527-531.
39. Nicholls D.G., Chalmers S. The integration of mitochondrial calcium transport and storage. J. Bioenerg. Biomembr. 2004, 36:277-281.
40. Carafoli E., Lehninger A.L. A survey of the interaction of calcium ions with mitochondria from different tissues and species. Biochem. J. 1971, 122:681-690.
41. 2+ transport by coupled Trypanosoma cruzi mitochondria in situ. J. Biol. Chem. 1989, 264:108-111.
42. 2+ concentrations. Biochim. Biophys. Acta 1973, 305:41-51.
43. Uribe S., Rangel P., Pardo J.P. Interactions of calcium with yeast mitochondria. Cell Calcium 1992, 13:211-217.
44. Perocchi F., Gohil V.M., Girgis H.S., Bao X.R., McCombs J.E., Palmer A.E., Mootha V.K. MICU1 encodes a mitochondrial EF hand protein required for Ca(2+) uptake. Nature 2010, 467:291-296.
45. Chandra S., Kable E.P., Morrison G.H., Webb W.W. Calcium sequestration in the Golgi apparatus of cultured mammalian cells revealed by laser scanning confocal microscopy and ion microscopy. J. Cell Sci. 1991, 100(Pt 4):747-752.
46. Missiaen L., Dode L., Vanoevelen J., Raeymaekers L., Wuytack F. Calcium in the Golgi apparatus. Cell Calcium 2007, 41:405-416.
47. Yáñez M., Gil-Longo J., Campos-Toimil M. Calcium binding proteins. Adv. Exp. Med. Biol. 2012, 740:461-482.
48. Sekharudu Y.C., Sundaralingam M. A structure-function relationship for the calcium affinities of regulatory proteins containing 'EF-hand' pairs. Protein Eng. 1988, 2:139-146.
49. Lin P., Le-Niculescu H., Hofmeister R., McCaffery J.M., Jin M., Hennemann H., McQuistan T., De Vries L., Farquhar M.G. The mammalian calcium-binding protein, nucleobindin (CALNUC), is a Golgi resident protein. J. Cell Biol. 1998, 141:1515-1527.
50. 2+)-binding protein localized to the Golgi lumen. J. Cell Biol. 1996, 133:257-268.
51. Morel-Huaux V.M., Pypaert M., Wouters S., Tartakoff A.M., Jurgan U., Gevaert K., Courtoy P.J. The calcium-binding protein p54/NEFA is a novel luminal resident of medial Golgi cisternae that traffics independently of mannosidase II. Eur. J. Cell Biol. 2002, 81:87-100.
52. Aradhyam G.K., Balivada L.M., Kanuru M., Vadivel P., Vidhya B.S. Calnuc: emerging roles in calcium signaling and human diseases. IUBMB Life 2010, 62:436-446.
53. 2+ ion-pump PMR1 links elevation of cytosolic Ca(2+) levels to α-synuclein toxicity in Parkinson's disease models. Cell Death Differ. 2013, 20:465-477.
54. Missiaen L., Raeymaekers L., Dode L., Vanoevelen J., Van Baelen K., Parys J.B., Callewaert G., De Smedt H., Segaert S., Wuytack F. SPCA1 pumps and Hailey-Hailey disease. Biochem. Biophys. Res. Commun. 2004, 322:1204-1213.
55. Hailey H., Hailey H. Familial benign chronic pemphigus. Arch. Dermatol. Syphilol. 1939, 39:679-685.
56. Hashimoto K., Fujiwara K., Harada M., Setoyama M., Eto H. Junctional proteins of keratinocytes in Grover's disease, Hailey-Hailey's disease and Darier's disease. J. Dermatol. 1995, 22:159-170.
57. Metze D., Hamm H., Schorat A., Luger T. Involvement of the adherens junction-actin filament system in acantholytic dyskeratosis of Hailey-Hailey disease. A histological, ultrastructural, and histochemical study of lesional and non-lesional skin. J. Cutan. Pathol. 1996, 23:211-222.
58. Chun S.I., Whang K.C., Su W.P. Squamous cell carcinoma arising in Hailey-Hailey disease. J. Cutan. Pathol. 1988, 15:234-237.
59. Cockayne S.E., Rassl D.M., Thomas S.E. Squamous cell carcinoma arising in Hailey-Hailey disease of the vulva. Br. J. Dermatol. 2000, 142:540-542.
60. Mohr M.R., Erdag G., Shada A.L., Williams M.E., Slingluff C.L.J., Patterson J.W. Two patients with Hailey-Hailey disease, multiple primary melanomas, and other cancers. Arch. Dermatol. 2011, 147:211-215.
61. Hu Z., Bonifas J.M., Beech J., Bench G., Shigihara T., Ogawa H., Ikeda S., Mauro T., Epstein E.H.J. Mutations in ATP2C1, encoding a calcium pump, cause Hailey-Hailey disease. Nat. Genet. 2000, 24:61-65.
62. Sudbrak R., Brown J., Dobson-Stone C., Carter S., Ramser J., White J., Healy E., Dissanayake M., Larregue M., Perrussel M., Lehrach H., Munro C.S., Strachan T., Burge S., Hovnanian A., Monaco A.P. Hailey-Hailey disease is caused by mutations in ATP2C1 encoding a novel Ca(2+) pump. Hum. Mol. Genet. 2000, 9:1131-1140.
63. Jiang Z., Hu Z., Zeng L., Lu W., Zhang H., Li T., Xiao H. The role of the Golgi apparatus in oxidative stress: is this organelle less significant than mitochondria?. Free Radic. Biol. Med. 2011, 50:907-917.
64. Okunade G.W., Miller M.L., Azhar M., Andringa A., Sanford L.P., Doetschman T., Prasad V., Shull G.E. Loss of the Atp2c1 secretory pathway Ca(2+)-ATPase (SPCA1) in mice causes Golgi stress, apoptosis, and midgestational death in homozygous embryos and squamous cell tumors in adult heterozygotes. J. Biol. Chem. 2007, 282:26517-26527.
65. Cialfi S., Oliviero C., Ceccarelli S., Marchese C., Barbieri L., Biolcati G., Uccelletti D., Palleschi C., Barboni L., De Bernardo C., Grammatico P., Magrelli A., Salvatore M., Taruscio D., Frati L., Gulino A., Screpanti I., Talora C. Complex multipathways alterations and oxidative stress are associated with Hailey-Hailey disease. Br. J. Dermatol. 2010, 162:518-526.
66. Raiko L., Siljamäki E., Mahoney M.G., Putaala H., Suominen E., Peltonen J., Peltonen S. Hailey-Hailey disease and tight junctions: claudins 1 and 4 are regulated by ATP2C1 gene encoding Ca(2+)/Mn(2+) ATPase SPCA1 in cultured keratinocytes. Exp. Dermatol. 2012, 21:586-591.
67. Manca S., Magrelli A., Cialfi S., Lefort K., Ambra R., Alimandi M., Biolcati G., Uccelletti D., Palleschi C., Screpanti I., Candi E., Melino G., Salvatore M., Taruscio D., Talora C. Oxidative stress activation of miR-125b is part of the molecular switch for Hailey-Hailey disease manifestation. Exp. Dermatol. 2011, 20:932-937.
68. Talora C., Campese A.F., Bellavia D., Felli M.P., Vacca A., Gulino A., Screpanti I. Notch signaling and diseases: an evolutionary journey from a simple beginning to complex outcomes. Biochim. Biophys. Acta 2008, 1782:489-497.
69. Carroll D.K., Brugge J.S., Attardi L.D. p63, cell adhesion and survival. Cell Cycle 2007, 6:255-261.
70. Bessa G.R., Grazziotin T.C., Manzoni A.P., Weber M.B., Bonamigo R.R. Hailey-Hailey disease treatment with Botulinum toxin type A. An. Bras. Dermatol. 2010, 85:717-722.
71. Burge S.M. Hailey-Hailey disease: the clinical features, response to treatment and prognosis. Br. J. Dermatol. 1992, 126:275-282.
72. Le Saché-de Peufeilhoux L., Raynaud E., Bouchardeau A., Fraitag S., Bodemer C. Familial benign chronic pemphigus and doxycycline: a review of 6 cases. J. Eur. Acad. Dermatol. Venereol. 2012, 28:370-373.
73. Almeida L., Grossman M.E. Benign familial pemphigus complicated by herpes simplex virus. Cutis 1989, 44:261-262.
74. Ikeda S., Suga Y., Ogawa H. Successful management of Hailey-Hailey disease with potent topical steroid ointment. J. Dermatol. Sci. 1993, 5:205-211.
75. Christian M.M., Moy R.L. Treatment of Hailey-Hailey disease (or benign familial pemphigus) using short pulsed and short dwell time carbon dioxide lasers. Dermatol. Surg. 1999, 25:661-663.
76. Pretel-Irazabal M., Lera-Imbuluzqueta J.M., España-Alonso A. Carbon dioxide laser treatment in Hailey-Hailey disease: a series of 8 patients. Actas Dermosifiliogr. 2013, 104:325-333.
77. Menz P., Jackson I.T., Connolly S. Surgical control of Hailey-Hailey disease. Br. J. Plast. Surg. 1987, 40:557-561.
78. Ruiz-Rodriguez R., Alvarez J.G., Jaén P., Acevedo A., Córdoba S. Photodynamic therapy with 5-aminolevulinic acid for recalcitrant familial benign pemphigus (Hailey-Hailey disease). J. Am. Acad. Dermatol. 2002, 47:740-742.
79. Kellermayer R., Szigeti R., Keeling K.M., Bedekovics T., Bedwell D.M. Aminoglycosides as potential pharmacogenetic agents in the treatment of Hailey-Hailey disease. J. Invest. Dermatol. 2006, 126:229-231.
80. Clancy J.P., Bebök Z., Ruiz F., King C., Jones J., Walker L., Greer H., Hong J., Wing L., Macaluso M., Lyrene R., Sorscher E.J., Bedwell D.M. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 2001, 163:1683-1692.
81. Aoki T., Hashimoto H., Koseki S., Hozumi Y., Kondo S. 1alpha,24-dihydroxyvitamin D3 (tacalcitol) is effective against Hailey-Hailey disease both in vivo and in vitro. Br. J. Dermatol. 1998, 139:897-901.
82. Bianchi L., Chimenti M.S., Giunta A. Treatment of Hailey-Hailey disease with topical calcitriol. J. Am. Acad. Dermatol. 2004, 51:475-476.
83. Jeon S.Y., Ha S.M., Ko D.Y., Song K.H., Kim K.H. Hailey-Hailey disease treated with topical tacalcitol. Ann. Dermatol. 2013, 25:389-390.
84. Rajpara S.M., King C.M. Hailey-Hailey disease responsive to topical calcitriol. Br. J. Dermatol. 2005, 152:816-817.
85. Bikle D.D. Vitamin D metabolism and function in the skin. Mol. Cell. Endocrinol. 2011, 347:80-89.
86. Ratnam A.V., Bikle D.D., Cho J.K. 1,25 dihydroxyvitamin D3 enhances the calcium response of keratinocytes. J. Cell. Physiol. 1999, 178:188-196.
87. Mauro T.M. Yeast researchers consider Hailey-Hailey disease. J. Investig. Dermatol. 2004, 123:xxii.
88. Ton V.-K., Rao R. Expression of Hailey-Hailey disease mutations in yeast. J. Investig. Dermatol. 2004, 123:1192.
89. 2+-ATPase KlPmr1p function is required for oxidative stress response by controlling the expression of the heat-shock element HSP60 in Kluyveromyces lactis. Mol. Biol. Cell 2005, 16:4636-4647.
90. 2+-ATPase. FEBS Lett. 1996, 392:194-200.
91. Lapinskas P.J., Cunningham K.W., Liu X.F., Fink G.R., Culotta V.C. Mutations in PMR1 suppress oxidative damage in yeast cells lacking superoxide dismutase. Mol. Cell. Biol. 1995, 15:1382-1388.
92. 2+ ATPase family. Cell 1989, 58:133-145.
93. 2+-ATPase, reveals residues critical for ion selectivity and transport. J. Biol. Chem. 2000, 275:23927-23932.
94. Antebi A., Fink G.R. The yeast Ca(2+)-ATPase homologue, PMR1, is required for normal Golgi function and localizes in a novel Golgi-like distribution. Mol. Biol. Cell 1992, 3:633-654.
95. 2+ required for glycosylation, sorting, and endoplasmic reticulum-associated protein degradation. Mol. Biol. Cell 1998, 9:1149-1162.
96. Ramos-Castañeda J., Park Y.N., Liu M., Hauser K., Rudolph H., Shull G.E., Jonkman M.F., Mori K., Ikeda S., Ogawa H., Arvan P. Deficiency of ATP2C1, a Golgi ion pump, induces secretory pathway defects in endoplasmic reticulum (ER)-associated degradation and sensitivity to ER stress. J. Biol. Chem. 2005, 280:9467-9473.
97. Suzuki C., Shimma Y.I. P-type ATPase spf1 mutants show a novel resistance mechanism for the killer toxin SMKT. Mol. Microbiol. 1999, 32:813-823.
98. Garcia-Rodriguez N., Diaz de la Loza M.D., Andreson B., Monje-Casas F., Rothstein R., Wellinger R.E. Impaired manganese metabolism causes mitotic misregulation. J. Biol. Chem. 2012, 287:18717-18729.
99. Funakoshi M., Kajiwara R., Goda T., Nishimoto T., Kobayashi H. Isolation and characterisation of a mutation in the PMR1 gene encoding a Golgi membrane ATPase, which causes hypersensitivity to over-expression of Clb3 in Saccharomyces cerevisiae. Mol. Gen. Genet. 2000, 264:29-36.
100. Yadav J., Muend S., Zhang Y., Rao R. A phenomics approach in yeast links proton and calcium pump function in the Golgi. Mol. Biol. Cell 2007, 18:1480-1489.
101. Garcia-Rodriguez N. Studies on the Effect of Manganese on DNA Metabolism and Cell Cycle 2012, University of Seville, Spain, (Ph.D. Thesis).
102. 2+-transport ATPases. Chem. Rev. 2009, 109:4733-4759.
103. Hofer A.M., Brown E.M. Extracellular calcium sensing and signalling. Nat. Rev. Mol. Cell Biol. 2003, 4:530-538.
104. Anelli T., Sitia R. Protein quality control in the early secretory pathway. EMBO J. 2008, 27:315-327.
105. Demaegd D., Foulquier F., Colinet A.S., Gremillon L., Legrand D., Mariot P., Peiter E., Van Schaftingen E., Matthijs G., Morsomme P. Newly characterized Golgi-localized family of proteins is involved in calcium and pH homeostasis in yeast and human cells. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:6859-6864.
106. Foulquier F. COG defects, birth and rise!. Biochim. Biophys. Acta 2009, 1792:896-902.
107. Foulquier F., Amyere M., Jaeken J., Zeevaert R., Schollen E., Race V., Bammens R., Morelle W., Rosnoblet C., Legrand D., Demaegd D., Buist N., Cheillan D., Guffon N., Morsomme P., Annaert W., Freeze H.H., Van Schaftingen E., Vikkula M., Matthijs G. TMEM165 deficiency causes a congenital disorder of glycosylation. Am. J. Hum. Genet. 2012, 91:15-26.
108. Jaeken J., Matthijs G. Congenital disorders of glycosylation: a rapidly expanding disease family. Annu. Rev. Genomics Hum. Genet. 2007, 8:261-278.
109. Jaeken J., Hennet T., Matthijs G., Freeze H.H. CDG nomenclature: time for a change!. Biochim. Biophys. Acta 2009, 1792:825-826.
110. Schachter H., Freeze H.H. Glycosylation diseases: quo vadis?. Biochim. Biophys. Acta 2009, 1792:925-930.
111. Mandal D., Woolf T.B., Rao R. Manganese selectivity of pmr1, the yeast secretory pathway ion pump, is defined by residue gln783 in transmembrane segment 6. Residue Asp778 is essential for cation transport. J. Biol. Chem. 2000, 275:23933-23938.
112. Wei Y., Marchi V., Wang R., Rao R. An N-terminal EF hand-like motif modulates ion transport by Pmr1, the yeast Golgi Ca(2+)/Mn(2+)-ATPase. Biochemistry 1999, 38:14534-14541.
113. Chao S.C., Tsai Y.M., Yang M.H. Mutation analysis of ATP2C1 gene in Taiwanese patients with Hailey-Hailey disease. Br. J. Dermatol. 2002, 146:595-600.
114. Dobson-Stone C., Fairclough R., Dunne E., Brown J., Dissanayake M., Munro C.S., Strachan T., Burge S., Sudbrak R., Monaco A.P., Hovnanian A. Hailey-Hailey disease: molecular and clinical characterization of novel mutations in the ATP2C1 gene. J. Invest. Dermatol. 2002, 118:338-343.
115. Ikeda S., Shigihara T., Mayuzumi N., Yu X., Ogawa H. Mutations of ATP2C1 in Japanese patients with Hailey-Hailey disease: intrafamilial and interfamilial phenotype variations and lack of correlation with mutation patterns. J. Invest. Dermatol. 2001, 117:1654-1656.
116. Li H., Sun X.K., Zhu X.J. Four novel mutations in ATP2C1 found in Chinese patients with Hailey-Hailey disease. Br. J. Dermatol. 2003, 149:471-474.
117. Chao S.C., Lee J.Y., Wu M.C., Hsu M.M. A novel splice mutation in the ATP2C1 gene in a woman with concomitant psoriasis vulgaris and disseminated Hailey-Hailey disease. Int. J. Dermatol. 2012, 51:947-951.
118. Fairclough R.J., Lonie L., Van Baelen K., Haftek M., Munro C.S., Burge S.M., Hovnanian A. Hailey-Hailey disease: identification of novel mutations in ATP2C1 and effect of missense mutation A528P on protein expression levels. J. Invest. Dermatol. 2004, 123:67-71.
119. Hamada T., Fukuda S., Sakaguchi S., Yasumoto S., Kim S.C., Hashimoto T. Molecular and clinical characterization in Japanese and Korean patients with Hailey-Hailey disease: six new mutations in the ATP2C1 gene. J. Dermatol. Sci. 2008, 51:31-36.
120. Rácz E., Csikós M., Kárpáti S. Novel mutations in the ATP2C1 gene in two patients with Hailey-Hailey disease. Clin. Exp. Dermatol. 2005, 30:575-577.
121. Yokota K., Yasukawa K., Shimizu H. Analysis of ATP2C1 gene mutation in 10 unrelated Japanese families with Hailey-Hailey disease. J. Invest. Dermatol. 2002, 118:550-551.